<DOC>
	<DOCNO>NCT01994837</DOCNO>
	<brief_summary>A Phase 2 , Open-Label , Multicenter study evaluate preliminary efficacy safety ABT-199 administer orally patient AML .</brief_summary>
	<brief_title>A Phase 2 Study ABT-199 Subjects With Acute Myelogenous Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Histological cytological confirmation relapse refractory AML ( World Health Organization ( WHO ) classification ) untreated AML patient unfit intensive therapy . 2 . Subject Eastern Cooperative Oncology Group ( ECOG ) Performance score 0 2 . 3 . Subject must adequate renal function demonstrate calculated creatinine clearance â‰¥ 50 mL/min ; determine via urine collection 24hour creatinine clearance Cockcroft Gault formula use ideal body mass ( IBM ) instead mass . 4 . Subject must adequate liver function . 1 . Subject receive acute anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal investigational therapy within 14 day 5 halflives ( whichever short ) prior first dose ABT199 . 2 . Subject receive monoclonal antibody antineoplastic intent within 8 week prior first dose study drug . 3 . Subject receive Potent CYP3A inducer ( rifampin , carbamazepine , phenytoin St. John 's wort Warfarin require use warfarin ( due potential drugdrug interaction may potentially increase exposure warfarin complication effect ) within 7 day prior first dose study drug . 4 . Subject receive CYP3A inhibitor ( fluconazole , ketoconazole , clarithromycin ) within 5 day prior first dose study drug . 5 . Subject white blood cell count &gt; 25 x 10^9/L . 6 . Subject acute promyelocytic leukemia ( FrenchAmericanBritish Class M3 AML ) . 7 . Subjects know active CNS disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>GDC-0199</keyword>
	<keyword>ABT-199</keyword>
	<keyword>Myeloid Leukemia</keyword>
</DOC>